Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Etizolam→

Etizolam Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
40054-69-1
Molecular formula
C17H15ClN4S
Molecular weight
342.8 g/mol
Drug class
Thienodiazepinebenzodiazepine-site positive allosteric modulator
Mechanism of action
Acts at the benzodiazepine site of GABA-A receptors and enhances GABA-mediated inhibitory neurotransmission, producing anxiolytic, sedative and hypnotic effects. Etizolam is a thienodiazepine rather than a conventional benzodiazepine.
Indications / reported uses
  • Used as a prescription anxiolytic or hypnotic in certain countries for anxiety and sleep disorders; not approved for medical use in the United States, and regulatory status varies by jurisdiction

Sources: US DEA Drug and Chemical Evaluation — Etizolam (May 2026) · WHO Expert Committee on Drug Dependence — Etizolam · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Etizolam Environmental Risk Assessment (ERA) (the Etizolam ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.